Five Key Takeaways from BeOne Medicines Second Quarter 2026 Results
August 2026
“BeOne’s second quarter 2026 financial results reflect continued momentum across our business and meaningful progress in reaching more patients around the world. These results demonstrate both the strength of our business today and the opportunities ahead.”
-John V. Oyler, Co-Founder, Chairman, and CEO
Five Key Takeaways from BeOne’s Second Quarter 2026 Results
At BeOne, we believe progress against cancer is built through many saves: the scientific discovery that opens a new path, the clinical milestone that creates new possibilities, and the execution that helps innovative medicines reach patients around the world. That momentum was on full display in the second quarter of 2026.
- Revenue Reached $1.7 Billion
BeOne reported $1.7 billion in total revenue, representing 30% year-over-year growth. The performance reflects established leadership in hematology as we work to advance on the deepest and most diverse solid tumor pipelines in the industry. - Profitability Continued to Increase
The company generated $237 million in GAAP net income and $2.05 diluted GAAP earnings per ADS, demonstrating increasing operating leverage and financial strength as BeOne continues to scale globally. - Gross Margin Improved to 90%
Gross margin increased to 90%, up from 87% in the prior-year period, driven by portfolio mix and productivity improvements. Stronger operational performance helps support future investment in both commercial execution and R&D. - Commercial Momentum Continued
The quarter included several important milestones across BeOne’s commercial portfolio:- 31% growth in global sales of our BTK inhibitor, reaching $1.2 billion.
- U.S. FDA accelerated approval of our BCL-2 inhibitor for adults with relapsed or refractory mantle cell lymphoma.
- Japan regulatory approval of our PD-1 inhibitor for adults with first-line gastric cancer.
- Meaningful Pipeline Progress
Our pipeline progress in Q2 included:- Positive topline results from the Phase 3 MANGROVE study in treatment-naïve mantle cell lymphoma;
- Continued advancement of our BTK degrader, tacabrutideg, through potentially registrational Phase 2 studies;
- On track progress in our Phase 3 CaDAnCe-304 trial against pirtobrutinib;
- Five solid tumor programs achieving clinical proof of concept and advancing toward pivotal development;
- Receiving FDA Orphan Drug Designation for our PRMT5 inhibitor in pancreatic ductal adenocarcinoma.
Looking Ahead
As BeOne continues to strengthen its commercial portfolio and advance its pipeline, the company’s second quarter results demonstrate how financial performance, scientific progress, and operational execution work together to create impact.
Because progress against cancer doesn’t happen all at once. It is built through discoveries, approvals, research milestones, and the relentless grit of the people behind them.
Our most important measure of success is not found in metrics alone, but the impact we have on patients and families around the world who have benefited from our medicines.
Together, we are how the world stops cancer.
